Acute myeloid leukemia with a novel CPSF6‐RARG variant is sensitive to homoharringtonine and cytarabine chemotherapy

急性早幼粒细胞白血病 阿糖胞苷 高三尖杉酯碱 髓系白血病 维甲酸 生物 融合转录本 癌症研究 白血病 免疫学 内科学 融合基因 医学 遗传学 基因
作者
Zhanglin Zhang,Mei Jiang,Gautam Borthakur,Shu‐Qing Luan,Xianbao Huang,Guilin Tang,Qian Xu,Dexiang Ji,Andrew D. Boyer,Fēi Li,Ruibin Huang,M. James You
出处
期刊:American Journal of Hematology [Wiley]
卷期号:95 (2) 被引量:20
标识
DOI:10.1002/ajh.25689
摘要

Acute promyelocytic leukemia (APL) is characterized by the PML-RARA fusion gene, which is generated by chromosomal translocation t(15;17) (q22;q21), and can be induced differentiation by all-trans retinoic acid (ATRA) and arsenic.1 However, occasional acute myeloid leukemia (AML) cases with classic morphological, immunophenotypical, and clinical characteristics of APL are identified that do not have the PML-RARA fusion gene, and are resistant to ATRA and arsenic.2 Several reports have shown that some patients with AML resembling APL have retinoic acid receptor beta (RARB) or retinoic acid receptor gamma (RARG) rearrangement.3-5 Patients with CPSF6-RARG, a very rare occult fusion gene by inv(12q13;12q15), are difficult to diagnose; therefore, they are difficult to treat effectively.6-8 In this study, we report a case of AML, morphologically and immunophenotypically resembling APL, and carrying a novel CPSF6-RARG variant that was generated by the fusion of exon 5 of CPSF6, and exon 1 of RARG. Complete remission was achieved after treating the patient with a homoharringtonine (HA) and cytarabine chemotherapy regimen but not with differentiation-inducing therapy or conventional anthracycline plus cytarabine chemotherapy. A 55-year-old previously healthy man was admitted because of fever and pulmonary infection that did not respond to antibiotic treatment for 1 month. Blood tests showed a hemoglobin level of 76 g/L (normal range, 110-150 g/L), white blood cell count of 1.23 × 109/L (normal range, 4-9 × 109/L), and platelet count of 60 × 109/L (normal range, 100-300 × 109). The fibrinogen and D-dimer levels were 2.14 g/L (ref. 2.00-4.00 g/L) and 21.17 μg/mL (normal range, 0.00-0.55 μg/mL), respectively. Prothrombin time and activated partial prothromboplastin time were 13.7 seconds (normal range, 10.5-13.0 seconds) and 38.1 seconds (normal range, 23-35 seconds), respectively. A bone marrow smear revealed hypercellularity, with 93% immature cells that consisted of predominantly abnormal hypergranular promyelocytes with occasional Auer rods (Figure S1A). Moreover, the blasts, including the promyelocytes, were strongly positive for myeloperoxidase (Figure S1B). Flow cytometric immunophenotypic studies demonstrated that the blasts were positive for CD13, CD33, CD117, and CD56 (Figure S1C) but negative for HLA-DR, CD34, CD38, CD15, CD14, CD7, CD2, CD3, CD4, CD8, CD19, CD20, and CD10. The presumptive diagnosis in this patient was APL, and he received ATRA starting on the first day of admission. However, dual-color dual-fusion fluorescence in situ hybridization (DCDF-FISH) with a specific probe for PML and RARA failed to detect the PML-RARA fusion transcript in the bone marrow sample (Figure S1D). A chromosomal analysis using GTG banding indicated a normal karyotype of 46,XY (Figure 1E). Myeloid-related fusion genes (MLL/ELL, MLL/AF17, MLL/AF6, MLL/AF9, MLL/AF10, AML1/ETO, dupMLL, NPM/RARA, PLZF/RARA, PML/RARA, NPM/MLF1, CBFβ/MYH1, DEK/CAN, HOX11, TLS/ERG, and EVI1) were negative by RT-PCR. No hotspot mutations were identified by exon sequencing. To search for the potential fusion gene, we performed RNA sequencing of the bone marrow samples with a HiSeq 2500 system (Illumina, Inc., San Diego, CA, USA) and found 21 fusion genes with a probability of more than 80% using deFuse inspector software (Figure 1A). The sequences of the 21 fusion genes were aligned in the NCBI database (https://blast.ncbi.nlm.nih.gov), and exon 5 of CPSF6 was fused to exon 1 of the RARG fusion gene in frame, which is expected to result in a fusion protein with 828 AMino acids (Figure 1B). To confirm the fusion, we performed RT-PCR using the bone marrow sample and the following primers: forward (at CPSF6 exon 4), 5′-AGACTGGCTTCTACATACTG-3′ and reverse (at RARG exon 2), 5′-AGACTGGCTTCTACATACTG-3′. As expected, a band of approximately 500 bp was visualized by electrophoresis in the bone marrow but not in the NB4 cell line, an APL cell line (Figure 1C). Sanger sequencing revealed that the fusion gene was the fusion of CPSF6 exon 5 with RARG exon 1 (Figure 1D). On the basis of our morphological and immunophenotypical findings, we made a presumptive diagnosis of APL. The patient was treated with 40 mg of ATRA per day for 20 days. Arsenic trioxide (ATO) (10 mg per day) was added starting on day 21. After 1 month of treatment, 74% of the bone marrow cells were promyelocytes. Because the patient demonstrated complete resistance to ATRA and ATO, the treatment was switched to idamycin (10 mg d1-4) and Ara-C (150 mg d1-7) as an induction therapy. The blast cells in the bone marrow were 79% after 20 days of treatment. The patient discontinued therapy and was discharged on September 29, 2018. He was re-admitted on November 6, 2018, and underwent a course of homoharringtonine (4 mg d1-7) and Ara-C (150 mg d1-7) (Figure 1E). He has been in complete remission since December 2018 (Table S1). Because both CPSF6 and RARG genes are located at 12q1, it is difficult to detect the CPSF6-RARG fusion gene using traditional genetic and molecular biological technologies. With the application of second-generation sequencing technology in the clinical diagnosis, four patients were reported with CPSF6-RARG, and one with RARG-CPSF6.6-9 All of the patients were morphologically diagnosed with APL, suggesting that their disease had a similar pathogenesis to that of APL. However, none of the patients with CPSF6-RARG or RARG-CPSF6 experienced a response to ATRA and ATO, suggesting that it is a novel subtype of AML. In previous reports, the fusion sites of CPSF6 were located at the terminal of exon 4 in four patients with CPSF6-RARG, but the fusion sites of RARG varied greatly (1 case at exon 1, 1 at exon 2, and 2 at exon 4).6-8 In our patient, the CPSF6-RARG variant was the longest, and the fusion site was exon 5 of CPSF6 with exon 1 of RARG. However, the role of different transcripts in the pathogenesis and prognosis of AML remains to be determined. Patients with this novel translocation are resistant to ATRA and arsenic, while conventional anthracycline plus cytarabine chemotherapy is equally ineffective.6-8 Homoharringtonine, which was first isolated from cephalotaxus plant alkaloid, inhibits protein translation and induces apoptosis in various cell lines of hematological malignancies in the G1 and G2 phases.10 It has been widely used in the treatment of AML, chronic myeloid leukemia, and myelodysplastic syndrome since the 1970s.11-13 A recent study found that the homoharringtonine chemotherapy regimen is effective in inducing remission in patients with refractory and relapsed AML.14 We treated our patient with the homoharringtonine regimen after the patient failed to experience a response to ATRA, ATO, and conventional idamycin and Ara-C chemotherapy. After one course of treatment, he achieved a complete remission, suggesting that homoharringtonine is a very effective drug for AML with CPSF6-RARG. In summary, we identified a novel CPSF6-RARG transcript in a patient with AML that resembled APL and provided evidence that homoharringtonine is effective as a backbone drug for the treatment of AML with CPSF6-RARG. It would be very interesting to determine whether the same treatment would be effective for AML with other types of RARG rearrangements. This work was supported by the Institutional Research Grant of The University of Texas MD Anderson Cancer Center. The authors declare no competing financial interests. Z.L.Z., M.J., and S.Q.L. performed the experiments. X.B.H., Q.X., D.J., L.F., and H.R.B. performed the clinical analyses. Z.L.Z., G.B., G.T., A.D.B., L.F., H.R.B., and M.J.Y. wrote the manuscript. Figure S1 Morphological, cytochemical, cytometric, and cytogenetic assessment of the patient's AML bone marrow sample. (A) Frequent promyelocytes with hypergranulated cytoplasm and invaginated nuclei are shown (Wright-Giemsa-stained bone marrow smear, × 1000). (B) Myeloperoxidase stain showed strong positivity in AML (×1000). (C) Flow cytometric analysis showed that CD45-dim blasts were gated. The blasts expressed CD33 and CD13, partially expressed CD117 and CD56, and did not express CD34, CD7, CD38, HLA-DR, or other myeloid and lymphoid markers. MON, LYM and DEB are monocytes, lymphocytes, and debris, respectively. (D) Interphase FISH revealed the absence of PML-RARA fusion signals in AML using PML-RARA dual-color, dual-fusion translocation probes. (E) Cytogenetics analysis with G-banding revealed a normal male karyotype 46, XY [20]. Table S1 Laboratory examination and maintenance therapy regimen Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
TianlangPan发布了新的文献求助10
刚刚
科研通AI5应助端庄的学姐采纳,获得10
刚刚
1秒前
狂野芷蕾完成签到 ,获得积分20
2秒前
李繁蕊发布了新的文献求助10
2秒前
司空元正完成签到 ,获得积分10
3秒前
up完成签到 ,获得积分10
3秒前
Ava应助酷酷的小张采纳,获得10
4秒前
小白白发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
5秒前
治治治完成签到,获得积分10
7秒前
YanDongXu发布了新的文献求助10
9秒前
123发布了新的文献求助10
9秒前
TianlangPan完成签到,获得积分10
9秒前
njhuxs完成签到,获得积分10
10秒前
芬达完成签到 ,获得积分10
12秒前
yangminghan发布了新的文献求助10
12秒前
蜂蜜小熊完成签到 ,获得积分10
14秒前
15秒前
15秒前
15秒前
清脆的巧凡应助Dawn采纳,获得20
16秒前
16秒前
田様应助今夜不设防采纳,获得10
16秒前
华仔应助Nikko采纳,获得10
16秒前
我是老大应助Brain采纳,获得10
18秒前
星辰大海应助KKKpumc采纳,获得10
18秒前
至乐无乐完成签到 ,获得积分10
19秒前
xinglonglin完成签到,获得积分10
19秒前
Yep0672发布了新的文献求助10
20秒前
20秒前
Vera完成签到,获得积分10
21秒前
酷波er应助龙仔采纳,获得10
21秒前
21秒前
共享精神应助123采纳,获得10
21秒前
22秒前
22秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975953
求助须知:如何正确求助?哪些是违规求助? 3520269
关于积分的说明 11201866
捐赠科研通 3256738
什么是DOI,文献DOI怎么找? 1798436
邀请新用户注册赠送积分活动 877578
科研通“疑难数据库(出版商)”最低求助积分说明 806464